PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.35%
G&A change of 60.35% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
117.22%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
89.95%
Operating expenses growth above 1.5x AXSM's 6.62%. Michael Burry would check for inefficiency.
89.95%
Total costs growth above 1.5x AXSM's 8.31%. Michael Burry would check for inefficiency.
-4.24%
Interest expense reduction while AXSM shows 24.56% growth. Joel Greenblatt would examine advantage.
100.53%
D&A growth while AXSM reduces D&A. John Neff would investigate differences.
79.29%
EBITDA growth exceeding 1.5x AXSM's 35.57%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-95.43%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-104.55%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-100.00%
Pre-tax income decline while AXSM shows 17.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.40%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
-134.36%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-134.21%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-134.21%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.